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Abstract
Background
Like a growing number of rapidly developing countries, India has begun to develop a system
for large-scale community-based screening for diabetes. We sought to identify the implica-
tions of using alternative screening instruments to detect people with undiagnosed type 2 di-
abetes among diverse populations across India.
Methods and Findings
We developed and validated a microsimulation model that incorporated data from 58 stud-
ies from across the country into a nationally representative sample of Indians aged 25–65 y
old. We estimated the diagnostic and health system implications of three major survey-
based screening instruments and random glucometer-based screening. Of the 567 million
Indians eligible for screening, depending on which of four screening approaches is utilized,
between 158 and 306 million would be expected to screen as “high risk” for type 2 diabetes,
and be referred for confirmatory testing. Between 26 million and 37 million of these people
would be expected to meet international diagnostic criteria for diabetes, but between 126
million and 273 million would be “false positives.” The ratio of false positives to true positives
varied from 3.9 (when using random glucose screening) to 8.2 (when using a survey-based
screening instrument) in our model. The cost per case found would be expected to be from
US$5.28 (when using random glucose screening) to US$17.06 (when using a survey-
based screening instrument), presenting a total cost of between US$169 and US$567
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million. The major limitation of our analysis is its dependence on published cohort studies
that are unlikely fully to capture the poorest and most rural areas of the country. Because
these areas are thought to have the lowest diabetes prevalence, this may result in overesti-
mation of the efficacy and health benefits of screening.
Conclusions
Large-scale community-based screening is anticipated to produce a large number of false-
positive results, particularly if using currently available survey-based screening instruments.
Resource allocators should consider the health system burden of screening and confirmato-
ry testing when instituting large-scale community-based screening for diabetes.
Introduction
Type 2 diabetes has increased in prevalence at an alarming rate in rapidly developing countries
such as India and China [1–4]. Most people with diabetes in these countries are undiagnosed;
hence, community-based screening of adults for diabetes has been suggested [5–8]. In India,
for example, a recently initiated program has already screened as many as 53 million adults in
both urban and rural communities, using either survey-based instruments (i.e., risk-scoring
questionnaires) or random (i.e., not necessarily fasting) blood glucose testing [9]. Individuals
identified as high risk through these screening strategies are typically referred for fasting blood
glucose tests to confirm the diagnosis. The Indian government plans to continue expanding
this large-scale screening program in coming years. However, despite its potentially large im-
pact, essentially no data have been collected to track the performance of the screening program
[10].
Large-scale screening for diabetes, like population-wide screening for any disease, must ful-
fill several key criteria: (i) that a reliably sensitive and specific screening instrument is available,
(ii) that facilities for diagnosis and treatment are available to those screened in order to initiate
early therapy, (iii) that there is an agreed-upon policy on whom to treat among those screened,
(iv) that the total cost of finding a case is included in estimating the impact of screening on
medical expenditure as a whole, and (v) that beneficial early therapy delivered to those individ-
uals newly diagnosed provides significant health advantages over the status quo [11]. In India,
numerous survey-based screening instruments have been constructed to identify persons with
a high risk of having undiagnosed diabetes among select sub-national Indian populations [6–
8], yet these have not been tested more widely among diverse populations given the absence of
large, nationally representative cohorts. The various risk factors incorporated into different in-
struments vary in prevalence among demographic populations and have very different associa-
tions with diabetes prevalence among urban and rural populations (e.g., [12]). Hence,
screening instruments developed among some subpopulations may not be optimal for a stan-
dardized, national program. Furthermore, it remains unclear how many resources must be de-
voted to confirmatory testing and subsequent treatment to deliver population health benefits.
In high-income countries, additional screening for high-risk, asymptomatic patients has not re-
sulted in a significant reduction in all-cause, cardiovascular, or diabetes-related mortality, or in
rates of diabetes-related microvascular complications such as blindness or renal failure [13,14].
We therefore constructed a microsimulation model to determine the implications of using
alternative proposed screening instruments to identify persons with a high risk of having
Diabetes Screening in India
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undiagnosed type 2 diabetes across diverse populations in India. We compared the three major
survey-based screening instruments proposed for use in India [6–8], as well as a random gluc-
ometer-based screening approach that has been initiated by some government offices [15], to
identify how different populations of people with diabetes in India would be detected through
these alternative screening strategies. Both the questionnaire-based screening instruments and
random glucometer-based screening are typically implemented through health “camps” that
adopt a “come one, come all” strategy, whereby any members of the public can potentially be
screened. We estimated rates of true- and false-positive and true- and false-negative screens,
the associated need for confirmatory testing, and the implications of therapy among those
found through the alternative screening approaches. We then calculated the number needed to
screen and treat (NNST) to prevent the incidence of one complication, since this is the ultimate
goal of early detection and treatment of type 2 diabetes; understanding the magnitude of bene-
fit in reduction of complication risk is an essential component of WHO screening criteria. We
also examined the costs of screening, including programmatic costs. We quantified the degree
of sensitivity and uncertainty in all of these calculations, identifying the extent to which infor-
mation available in currently available datasets could inform policy decisions despite continued
uncertainty about type 2 diabetes pathogenesis and prevalence in India.
Methods
Ethics committee approval for the Indian Migration Study (IMS) that was used to inform the
model was obtained from the All India Institute of Medical Sciences Ethics Committee, refer-
ence number A-60/4/8/2004; for the overall modeling research, ethics committee approval was
obtained from the Stanford University Institutional Review Board, reference number eP-
28811.
Model Overview
The modeling proceeded in three stages (see Fig 1). Full details of the modeling process, in-
cluding all input parameters, are provided in S1 Text, in accordance with international model
reporting guidelines [16]. Here, we provide an overview of the input data and calculation
approach.
First, we constructed a synthetic, nationally representative Indian population from a series
of sub-national cohort studies. We estimated the probability of having diabetes, the probability
of being diagnosed, and the correlated distribution between these probabilities and key diabetes
risk factors and co-morbidities (see Table 1 and S1 Fig) by age, sex, location, and income, using
mixed-effects meta-regression.
Second, we subjected each member of the synthetic population to each of three survey-
based screening instruments advocated for the detection of people with undiagnosed diabetes
in India (see Table 1) [6–8], implemented as an alternative to or in combination with random
glucose testing [15]. We tracked the number of people with previously undiagnosed diabetes
who would be detected through screening (true positives) or would be missed (false negatives),
and the number of people without diabetes who would be false positives or true negatives upon
screening, given the distribution of risk factors among these groups and the different risk fac-
tors incorporated into each instrument (Table 1).
Disease Burden
To estimate the burden of diabetes in India, we constructed a synthetic, nationally representa-
tive population for our model. We used United Nations estimates of India’s demographics
for the year 2015 [17], dividing a simulated population of India into cohorts defined by age
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(25–44 y old and 45–65 y old—the age groups among whom screening efforts are focused and
risk equations for complications have been validated [18,19]), sex, location (urban or rural),
and income (tertiles of the standard of living index, the standard metric of wealth in India
[20]). The lower-bound age cutoff was chosen based on the extremely small prevalence rates of
type 2 diabetes below age 25 y in India, such that screening performance always worsens when
including persons below this age; the upper-bound age cutoff was chosen based on the cutoff
commonly used in current screening efforts [10] and the absence of clinical trial data for the ef-
fects of glycemic control beyond this age [21].
We adopted a microsimulation approach, which means each member of the population was
simulated as an individual, and assigned a probability of having diabetes, a probability of being
undiagnosed if having diabetes, and a set of risk factor values and co-morbidities (itemized in
Table 1) correlated to these two probabilities. The advantage of this technique over older Mar-
kov modeling approaches is that microsimulation can capture complex individual screening
experiences and co-morbid disease histories, providing an estimate of heterogeneous effects in
a population as opposed to a simple population average among a given cohort. To assign indi-
viduals a diabetes disease status, determine whether they were likely to have been diagnosed if
they had diabetes, and provide them with associated risk factor values, we performed Monte
Fig 1. Model diagram. Individuals in the simulated population are assigned demographic characteristics based on the joint probabilities of being
in each age, sex, location, and income group given population demographic estimates for India. They are then assigned a probability of having
diabetes, either diagnosed or undiagnosed, and having various associated co-morbid risk factors, based on the joint probabilities of these prevalence rates
and factors listed in S2 Table and illustrated in S1 Fig based on prior population estimates for India. Individuals are then subject to the screening instruments
listed in Table 1, from which the model estimates positive and negative test results and subsequent diabetes complications with and without treatment.
doi:10.1371/journal.pmed.1001827.g001
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Carlo sampling from joint probability distributions of each of these probabilities and risk fac-
tors specific to their age, sex, income, and location group, estimated from a meta-regression on
58 cohort studies of diabetes published in India (n = 447,481; S1 Table). The cohort studies de-
scribe the prevalence of previously diagnosed diabetes (via self-report), the prevalence of previ-
ously undiagnosed diabetes (established through testing of the cohort populations per WHO
diagnostic criteria [22,23]), and the correlated frequency of the risk factors and co-morbid con-
ditions listed in Table 1. The overall probability distributions for diabetes disease, diabetes di-
agnosis, and associated risk factors were estimated through mixed-effects meta-regression
Table 1. Alternative risk factors included in survey-based screening instruments proposed for detecting undiagnosed diabetes in India [6–8].
Elements Included Risk Score Assigned in Each Instrument
Chaturvedi Risk Score Mohan Risk Score (Indian
Diabetes Risk Score)
Ramachandran Risk Score
Age +0 points: <40 y; +0 points: <35 y; +0 points: <30 y;
+4 points: 40–49 y; +20 points: 35–49 y; +10 points: 30–44 y;
+6 points: >49 y +30 points: 50 y +18 points: 45–59 y;
+19 points: >59 y
Blood pressure +0 points: <120 mm Hg systolic
and <80 mm Hg diastolic;
Not included Not included
+5 points: 120–139 mm Hg
systolic or 80–89 mm Hg
diastolic;
+7 points: 140 mm Hg systolic
or 90 mm Hg diastolic
Body mass index (BMI) Not included Not included +0 points: BMI < 25 kg/m2;
+7 points: BMI  25 kg/m2
Family history of diabetes +0 points: no history; +0 points: no history; +0 points: no history;
+4 points: history in parents or
siblings
+10 points: either parent with
history of diabetes;
+7 points: family history
(unspeciﬁed members)
+20 points: both parents with
history of diabetes
Physical activity level Not included +0 points: regular exercise
and strenuous work;
+0 points: moderate or
intense activity;
+20 points: regular exercise
or strenuous work;
+4 points: sedentary, light
physical activity only
+30 points: no exercise and
no strenuous work
Waist circumference +0 points: 75 cm (female), 80
cm (male);
+0 points: <80 cm (female),
<90 cm (male);
+0 points: <80 cm (female),
<85 cm (male);
+9 points: 76–84 cm (female),
81–89 cm (male);
+10 points: 80–89 cm
(female), 90–99 cm (male);
+5 points: 80 cm (female),
85 cm (male)
+12 points: >85 cm (female), >90
cm (male)
+20 points: 90 cm (female),
100 cm (male)
Total risk score possible 29 100 42
Score considered “positive” for risk of undiagnosed
diabetes, based on receiver operating characteristic
(ROC) curve
16 60 21
Criterion for diabetes diagnosis Fasting plasma glucose  7.0
mmol/l
2-h plasma glucose  11.1
mmol/l
2-h glucose (blood/plasma)
 11.1 mmol/l
The model subjects each simulated individual to each of the listed screening instruments to identify how many people would test positive or negative by
each instrument.
doi:10.1371/journal.pmed.1001827.t001
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accounting for changes in both disease prevalence and the probability of diagnosis over time.
This is a method to infer a population metric from a group of studies rather than a single co-
hort, accounting for variations in sampling among studies. Specifically, the model applied to
the total diabetes prevalence, the probability of being previously undiagnosed, and the risk fac-
tor value/co-morbidity prevalence observations y among the j studies was specified as [24]
yj ¼ b0 þ b1x1j þ . . .þ bnjxnj þ byyearþ uj þ εj ð1Þ
where x1i denotes the value of the ﬁrst moderator variable (e.g., percent of population in the
ﬁrst age category, 25–44 y old) in the ith study, and so on through all moderator classes of age,
sex, income, and location, and uj and εj are error terms referring to the amount of variability in
the true value of the outcome that is not accounted for by the moderators included in the
model and sample variances. The model was ﬁtted with weights using a standard “inverse-vari-
ance”method, with Monte Carlo sampling of estimates speciﬁc to the age, sex, income, and lo-
cation groups drawn from the probability distributions of the β coefﬁcients in the ﬁtted model.
Model details and outputs are provided in S1 Text and S2 Table. To assess the face validity of
our estimates, we compared them against three independent estimates from the Global Burden
of Metabolic Risk Factors of Chronic Diseases Collaborating Group [25], the WHO Study on
Global Ageing and Adult Health [26], and the International Diabetes Federation Diabetes
Atlas [4].
Screening Simulations
By applying each of the three screening instruments shown in Table 1 to the synthetic popula-
tion, we estimated how each screening instrument would perform in terms of sensitivity, speci-
ficity, positive predictive value, and negative predictive value. We then calculated the number
needed to screen (NNS) to detect one previously undiagnosed diabetes case, and computed the
overall number of persons deemed high risk, who would be referred for confirmatory testing in
both urban and rural locations, thereby providing an estimate of the burden of screening on
the healthcare system. Note that waist circumference is commonly used in the screening instru-
ments, given its superior performance compared to BMI in predicting type 2 diabetes risk
among South Asians [27–29]; however, BMI is included in one screening instrument, adopting
a lower cut point than the international obesity cut point, given that diabetes risk in South
Asians increases at a lower BMI, according to prior analyses [30,31].
The survey-based screening instruments listed in Table 1 were also compared to random
glucometer testing, for which a previous trial in rural India found that the optimal threshold
for screening by ROC curve analysis was6.1 mmol/l [15]. We estimated how many people
would exceed this threshold, incorporating the variation in blood glucose levels among both
persons with undiagnosed diabetes and persons without diabetes (S1 Fig) and the degree to
which the measures of random glucose via handheld glucometers in the Indian field trial dif-
fered from laboratory venous blood glucose test results (a standard deviation of 0.9 in Bland-
Altman analysis) [15]. In all cases, the screening instruments were followed by laboratory-
based fasting blood glucose testing for diagnosis because other methods (i.e., hemoglobin A1c)
are not widely available in India or other low- and middle-income countries at present. We ad-
ditionally determined what proportion of screened patients would be expected to be positive
for additional co-morbidities such as hypertension and obesity by noting the prevalence of
these conditions among the screen-positive patients (based on the joint distributions of co-
morbidities illustrated in S1 Fig). We also combined the survey-based instruments and random
glucometer testing to evaluate the sensitivity and specificity of both serial and parallel screening
scenarios, specifically simulating every possible combination of screening questionnaires and
Diabetes Screening in India
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random glucose testing in which either one test is followed by another in any order (and both
tests need to be positive for referral to confirmatory testing) or both tests are performed simul-
taneously (and either test needs to be positive to proceed to confirmatory testing). We applied
the instruments selectively to sub-populations defined by age, sex, urban/rural location, and in-
come status to examine variations in sensitivity and specificity.
Cost Analysis
To provide a sense of the typical costs associated with a screening program, we tabulated the
costs of both questionnaire-based and glucometer-based screening. We used World Health Or-
ganization CHOICE (CHOosing Interventions that are Cost-Effective) data [32], which pro-
vide the unit costs for personnel, operations, and materials for screening (itemized in S3
Table). Total costs including overhead expenditures were tabulated in 2014 US dollars for each
screening strategy over a 10-y implementation horizon at a standard 3% annual discount rate,
and were subjected to the sensitivity and uncertainty analyses described below.
Diabetes Complication Rates
To estimate the health benefits of screening, we used a mathematical model, the United King-
dom Prospective Diabetes Study (UKPDS) Outcomes Model 2, which includes South Asian–
specific disease progression parameters that have been validated among South Asians in both
the UK and India [33,34]. The risk equations in this model provide estimates of disease pro-
gression rates with and without treatment, including 20-y probabilities of heart disease events
(including ischemic heart disease, myocardial infarction, and heart failure), stroke, blindness,
diabetic ulcer (from peripheral arterial disease or neuropathy), and renal failure (see S1 Text
for endpoint definitions) [18,19,33]. We drew relevant biomarker values for individuals found
through screening using Monte Carlo sampling from the distribution of biomarkers among
people with previously undiagnosed diabetes in the IMS, in which the biomarkers were as-
sessed across India by age, sex, income, and location (see S1 Fig) [35]. We then estimated the
minimum NNST to prevent each of the diabetes complications, using the most optimistic and
aggressive targets for treatment (those set by the American Diabetes Association) to provide a
minimum floor estimate of the NNST [21]. These targets include lowering systolic blood pres-
sure to140 mm Hg, low-density lipoprotein (LDL) to2.6 mmol/l in those with no cardio-
vascular disease history (or1.8 mmol/l in those with a history of cardiovascular disease), and
hemoglobin A1c to7%. We additionally simulated the observed impact of behavioral risk
factor modification (i.e., lifestyle interventions) to reduce diabetes complications; although
these have not been found effective for cardiovascular endpoints, they potentially reduce the
risk of intermediate microvascular endpoints, which may translate into eventual reductions in
blindness and end-stage renal failure [36,37]. To estimate the minimum NNST values (i.e., the
most optimistic case), we simulated full reversal of risk, as per the UKPDS risk equations, and
simulated the case of universal treatment adherence by both providers and patients. This ap-
proach provides the best-case scenario for treatment outcomes. We also simulated treatment of
currently diagnosed patients with diabetes, similarly assigned biomarkers through Monte
Carlo sampling from their distribution of risk factors in the IMS [35]. We validated our esti-
mates against previously published example calculations to ensure correct application of the
model equations [18,19,33].
Diabetes Screening in India
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Sensitivity and Uncertainty Analyses
First, we estimated the minimum NNS to find one previously undiagnosed diabetes case if peo-
ple eligible for screening were subjected directly to fasting venous blood glucose testing rather
than the survey-based screening or random glucometer screening.
Second, we determined whether alternative thresholds for classifying persons as high risk
for each instrument would maximize the performance (i.e., increase the product of the sensitiv-
ity and specificity) of the instrument among the national population in the model, as compared
to the existing instrument cut points published previously based on sub-national studies
(Table 1). We constructed ROC curves on all tested instruments to identify optimal cut points
in the national population.
Finally, for uncertainty analysis, we ran our model 10,000 times while using Monte Carlo
sampling from the probability distributions of all input parameters to estimate stable 95% cred-
ible interval estimates around all model outcomes.
The model was programmed and implemented in R (v. 3.1.0, The R Foundation for Statisti-
cal Computing, Vienna).
Results
Disease Burden
Among the 586 million people anticipated to be aged 25–65 y old in India in the year 2015, the
mean diabetes prevalence rate was estimated as 12.0% in our model (95% CI: 8.4%–15.6%),
such that an estimated 70 million (95% CI: 50 million–91 million) people in this age group are
thought to have diabetes. In the simulated population, diabetes prevalence was slightly but not
significantly higher among men (12.3%, 95% CI: 9.4%–15.2%) than women (11.7%, 95% CI:
7.5%–16.0%), and higher among urban (18.6%, 95% CI: 13.1%–24.1%) than rural (8.7%, 95%
CI: 6.1%–11.2%) populations. An estimated 51 million of the 70 million persons with diabetes
are expected to be undiagnosed before the screening program (73.3%, 95% CI: 69.9%–76.7%),
with particularly high probabilities of being undiagnosed among women (83.1%, 95% CI:
81.3%–84.9%), low-income individuals (86.3%, 95% CI: 83.3%–89.3%), and rural populations
(80.0%, 95% CI: 77.2%–82.8%). Fully disaggregated estimates by demographic group are pro-
vided in S2 Table.
We compared our modeled estimates of diagnosed and total diabetes prevalence to three in-
dependent estimates [4,25,26]. As shown in S4 Table, the model closely matched the indepen-
dent estimates (<1.6% absolute difference) among all demographic categories and across all
years for which estimates are available from 2000 through 2014.
Screening Simulation
Table 2 summarizes the estimated sensitivity, specificity, positive predictive value, and negative
predictive value of each instrument, as well as the estimated NNS to find one undiagnosed dia-
betes case. The Chaturvedi risk score had the highest sensitivity (72.8%, versus 50.8% and
64.9% for the other two risk scores) and intermediate specificity (58.0%, versus 64.0% and
47.1%), and has the lowest NNS to find one undiagnosed diabetes case (15.2, versus 21.7 and
17.0).
By comparison with these survey-based screening instruments, random glucometer testing
offered greater specificity and therefore fewer false-positive results (see Table 2). Random gluc-
ometer testing would be expected to have 62.6% sensitivity (95% CI: 61.1%–64.2%) and 75.5%
specificity (95% CI: 75.2%–75.8%), requiring 17.6 persons (95% CI: 8.0–27.3) to be screened to
find one undiagnosed diabetes case.
Diabetes Screening in India
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Table 2. Comparison of instrument performance in published sub-national populations versus synthetic national population [6–8,15].
Performance
Category
Performance of Instrument in Detecting Undiagnosed Diabetes
Chaturvedi Risk Score Mohan Risk Score (Indian
Diabetes Risk Score)
Ramachandran Risk Score Random Point-of-Care
Glucose Testing (6.1
mmol/l)
Published
Estimates from
Sub-National
Cohorts
Estimate
from Model
(Synthetic
National
Cohort)
Published
Estimates
from Sub-
National
Cohorts
Estimate
from Model
(Synthetic
National
Cohort)
Published
Estimates from
Sub-National
Cohorts
Estimate
from Model
(Synthetic
National
Cohort)
Published
Estimates
from Sub-
National
Cohorts
Estimate
from Model
(Synthetic
National
Cohort)
Sensitivity 73% (68%–77%)
in industrial
workforce cohort
from multiple
Indian sites,
2001–2003; 66%
(95% CI: 59%–
73%) in urban
Delhi and rural
Haryana, 1991–
1994
72.8 (71.5–
74.1)
73% in urban
and rural
Chennai,
2001–2002
(no credible
intervals
reported)
50.8 (49.9–
51.8)
77% and 72% in
two cohorts from
six cities (2000);
74% in a cohort
from Chennai
(1995); 92% in
the South Asian
cohort from the
Health Survey for
England (1999)
(no credible
intervals
reported)
64.9 (63.9–
65.9)
78% in rural
Andhra
Pradesh (no
credible
intervals
reported)
62.6 (61.1–
64.2)
Speciﬁcity 56% (55%–57%)
in industrial
workforce cohort
from multiple
Indian sites,
2001–2003; 67%
(95% CI: 65%–
68%) in urban
Delhi and rural
Haryana, 1991–
1994
58.0 (57.5–
58.5)
60% in urban
and rural
Chennai,
2001–2002
(no credible
intervals
reported)
64.0 (63.5–
64.5)
60% and 59% in
two cohorts from
six cities (2000);
61% in a cohort
from Chennai
(1995); 26% in
the South Asian
cohort from the
Health Survey for
England (1999)
(no credible
intervals
reported)
47.1 (46.8–
47.4)
79% in rural
Andhra
Pradesh (no
credible
intervals
reported)
75.5 (75.2–
75.8)
Positive
predictive value
6% (5%–7%) in
industrial
workforce cohort
from multiple
Indian sites,
2001–2003; 10%
(8%–12%) in
urban Delhi and
rural Haryana,
1991–1994
14.7 (6.1–
23.2)
17% in urban
and rural
Chennai,
2001–2002
(no credible
intervals
reported)
11.1 (3.8–
18.5)
9% and 8% in
two cohorts from
six cities (2000);
12% in a cohort
from Chennai
(1995); 22% in
the South Asian
cohort from the
Health Survey for
England (1999)
(no credible
intervals
reported)
9.9 (3.2–
16.5)
15% in rural
Andhra
Pradesh (no
credible
intervals
reported)
18.4 (7.5–
29.2)
Negative
predictive value
98% (97%–99%)
in industrial
workforce cohort
from multiple
Indian sites,
2001–2003; 97%
(96%–98%) in
urban Delhi and
rural Haryana,
1991–1994
95.5 (92.6–
98.4)
95% in urban
and rural
Chennai,
2001–2002
(no credible
intervals
reported)
93.3 (88.8–
97.8)
98% and 98% in
two cohorts from
six cities (2000);
97% in a cohort
from Chennai
(1995); 94% in
the South Asian
cohort from the
Health Survey for
England (1999)
(no credible
intervals
reported)
93.5 (89.1–
97.8)
99% in rural
Andhra
Pradesh (no
credible
intervals
reported)
95.5 (92.5–
98.6)
(Continued)
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When projected to the population level (Fig 2; Table 3), we estimated that among 567 mil-
lion Indians aged 25–65 y eligible for screening, between 158 and 306 million people (27.9%–
53.9%) would screen positive and need referral for confirmatory testing. Between 26 and 37
million of the 51 million people with undiagnosed diabetes would be detected through any of
the screening instruments (50.9%–72.8% of the undiagnosed population), while between 14
and 25 million people with undiagnosed diabetes would be missed by the screening instru-
ments (27.2%–49.1% of those undiagnosed). Because of the lack of specificity of the survey-
based screening instruments, between 186 and 273 million people without diabetes (36.0%–
52.8% of those without diabetes screened) would be identified as false positives after confirma-
tory testing. For comparison, using a coin flip to refer people for confirmatory testing would
detect 50% of undiagnosed diabetes (25.5 million people) and refer about 258 million people
without diabetes to confirmatory testing. In the case of using random glucometer testing as an
alternative screening approach, the number of false-positive screens would be expected to be
reduced to 126 million (24.5% of those without diabetes screened). In other words, the ratio of
false to true positives would range from 3.9 (in the case of random glucometer testing) to
8.2 (in the case of the Ramachandran risk score). S5 Table provides a complete sensitivity anal-
ysis of screening outcomes if screening were targeted to certain demographic groups and loca-
tions, revealing a consistently high ratio of false to true positives across targeted screening
approaches.
Of note, the diabetes screening strategies would also serve to detect co-morbid diseases (S1
Fig). Of the proportion of persons screening positive through each instrument, between 23%
(Mohan risk score) and 79% (random glucometer testing) would also be expected to have hy-
pertension, and between 13% (Mohan risk score) and 56% (random glucometer testing) would
also be expected to meet the criterion for obesity (BMI 30 kg/m2).
We compared both serial and parallel screening scenarios, that is, when one instrument
would be followed by another in any order (and both tests would need to be positive for referral
to confirmatory testing) or both tests would be performed simultaneously (and either test
would need to be positive for referral to confirmatory testing), respectively. All of the parallel
screening scenarios had worse screening performance than the serial testing scenarios, because
of extremely high false- to true-positive ratios (S6 Table). Performing serial testing with
Table 2. (Continued)
Performance
Category
Performance of Instrument in Detecting Undiagnosed Diabetes
Chaturvedi Risk Score Mohan Risk Score (Indian
Diabetes Risk Score)
Ramachandran Risk Score Random Point-of-Care
Glucose Testing (6.1
mmol/l)
Published
Estimates from
Sub-National
Cohorts
Estimate
from Model
(Synthetic
National
Cohort)
Published
Estimates
from Sub-
National
Cohorts
Estimate
from Model
(Synthetic
National
Cohort)
Published
Estimates from
Sub-National
Cohorts
Estimate
from Model
(Synthetic
National
Cohort)
Published
Estimates
from Sub-
National
Cohorts
Estimate
from Model
(Synthetic
National
Cohort)
NNS to detect
one previously
undiagnosed
person with
diabetes
Not reported 15.2 (6.0–
23.5)
Not reported 21.7 (9.9–
33.6)
Not reported 17.0 (7.7–
26.3)
Not reported 17.6 (8.0–
27.3)
95% credible intervals are shown in parentheses. In all cases, the screening instrument is the ﬁrst-stage test, and individuals testing positive are then
subject to fasting blood glucose testing for diagnostic conﬁrmation.
doi:10.1371/journal.pmed.1001827.t002
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survey-based instruments after random glucometer testing also failed to improve screening
performance. The best screening performance, by contrast, was achieved through serial testing
when survey-based instruments were used first, followed by random glucose testing of a blood
sample with a handheld glucometer. This did not produce a significant improvement in sensi-
tivity over and above using random glucose testing alone, but the specificity of the screening
Fig 2. Population-level implications of large-scale screening for diabetes in India. FBG, fasting blood
glucose.
doi:10.1371/journal.pmed.1001827.g002
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could be improved to as much as 86% (reducing the number of false positives to 30 million, but
not significantly lowering the false- to true-positive ratio; S6 Table). Fig 3 illustrates the ROC
points for each screening instrument in isolation and when followed by random glucose
testing.
Cost Analysis
Table 3 summarizes the overall costs of each screening strategy, including estimated personnel,
operations, and material costs anticipated from each screening strategy. We found that al-
though the screening questionnaire costs were smaller than the costs of glucometer testing, this
cost differential is more than outweighed by the high cost of confirmatory testing for the larger
number of people who falsely screen positive by the questionnaire-based instruments. Overall
discounted costs for screening varied from a low-end estimate of US$169 million for random
glucometer testing (95% CI: US$120–US$221 million) to a high-end estimate of US$567 mil-
lion for the Ramachandran risk score (95% CI: US$398–US$737 million), which corresponds
Table 3. Health system burden associated with alternative diabetes screening approaches.
Population or Cost Burden by Instrument
Chaturvedi Risk Score Mohan Risk Score
(Indian Diabetes Risk
Score)
Ramachandran Risk
Score
Random Point-of-Care
Glucose Testing (6.1
mmol/l)
People with undiagnosed diabetes
(millions)
True-positive screens (percent of people
with undiagnosed diabetes screening
positive)
37.3 (37.3–37.3) (72.8%
of undiagnosed)
26.1 (26.0–26.1) (50.9%
of undiagnosed)
33.2 (33.2–33.3) (64.9% of
undiagnosed)
32.1 (32.1–32.1) (62.7%
of undiagnosed)
False-negative screens (percent of
people with undiagnosed diabetes
screening negative)
13.9 (13.9–13.9) (27.2%
of undiagnosed)
25.1 (25.1–25.2) (49.1%
of undiagnosed)
18.0 (18.0–18.0) (35.1% of
undiagnosed)
19.1 (19.1–19.1) (37.3%
of undiagnosed)
People without diabetes eligible for
screening (having previously
unknown diabetes status) (millions)
True-negative screens (percent of
people without diabetes screening
negative)
299.4 (299.4–299.5)
(58.1% of people without
diabetes screened)
330.2 (330.2–330.2)
(64% of people without
diabetes screened)
243.1 (243.1–243.2)
(47.2% of people without
diabetes screened)
389.5 (389.5–389.5)
(75.5% of people without
diabetes screened)
False-positive screens (percent of
people without diabetes screening
positive)
216.2 (216.2–216.2)
(41.9% of people without
diabetes screened)
185.5 (185.5–185.5)
(36% of people without
diabetes screened)
272.5 (272.5–272.5)
(52.8% of people without
diabetes screened)
126.2 (126.2–126.2)
(24.5% of people without
diabetes screened)
Total positive screens (percent of
those screened being referred to
conﬁrmatory testing) (millions)
253.5 (253.5–253.5)
(44.7% of those
screened)
211.6 (211.6–211.6)
(37.3% of those
screened)
305.8 (305.8–305.8)
(53.9% of those screened)
158.3 (158.3–158.3)
(27.9% of those
screened)
Estimated cost of implementation
including screening and conﬁrmatory
testing costs (millions of 2014 US
dollars)
$484.99 ($341.80–
$632.54)
$397.31 ($279.37–
$517.13)
$567.17 ($398.26–
$737.66)
$169.48 ($119.90–
$221.34)
Estimated screening and
conﬁrmatory testing cost per case
(true-positive screen) found (2014 US
dollars)
$13.01 ($9.17–$16.96) $15.25 ($10.73–$19.84) $17.06 ($11.98–$22.18) $5.28 ($3.74–$6.90)
The total number of people eligible for screening across instruments is 566.876 million (95% CI: 560.954–572.797 million). 95% credible intervals are
shown in parentheses. The table provides modeled estimates of how a simulated national population would be treated if screened through each
instrument detailed in Table 1. In each case, the number of false-positive results is very large.
doi:10.1371/journal.pmed.1001827.t003
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to a price per case found of between US$5.28 (95% CI: US$3.74–US$6.90) for random gluc-
ometer testing and US$17.06 (95% CI: US$11.98–US$22.18) for the Ramachandran risk score.
Diabetes Complication Rates
In order to provide a sense of the order-of-magnitude difference in potential benefits of treat-
ment among those with diabetes newly detected through screening versus those already diag-
nosed, S7 Table summarizes the model-based estimates of complication rates among the newly
screened population. As shown in the table, in the best-case treatment scenario the NNST
among those diagnosed through the community-based screening program was very high: on
the order of 789 people (95% CI: 225–2,213). Tallying the individual complications averted
through therapy, we found that 6.8% of the population newly diagnosed due to the screening
program (95% CI: 2.3%-28.6%) would be expected to avoid a diabetes complication over 20 y
in this best-case scenario. This corresponds to a median screening cost per case with complica-
tion prevented (i.e., excluding treatment costs) of US$1,908.17 (95% CI: US$562.00–US
$7,015.81) in the best-case scenario.
Fig 3. Comparison of each instrument in isolation, or when followed by random blood glucose testing (point-of-care capillary blood glucometer
test). Numbers refer to screening instruments: 1, Chaturvedi risk score; 2, Mohan risk score; 3, Ramachandran risk score; RBG refers to random blood
glucose testing. This plot displays the instrument performance using the cut points for positivity that were published in the literature previously to maximize
the area under the ROC curve upon testing of the instruments among sub-national populations [6–8,15]. We also compared the performance of the
instruments when recalibrated to the synthetic nationally representative population (S2 Fig).
doi:10.1371/journal.pmed.1001827.g003
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Sensitivity and Uncertainty Analyses
We also estimated the minimum NNS to find one previously undiagnosed diabetes case if peo-
ple eligible for screening were subjected to fasting venous blood glucose testing, bypassing the
survey-based screening instruments or random glucometer screening to skip directly to the
confirmatory testing phase. The NNS through this approach to find one previously undiag-
nosed diabetes case was estimated to be 11.1 (95% CI: 8.6–15.6), as compared to between 15.2
and 21.7 for the alternative screening instruments (Table 2).
We found that recalibrating each screening instrument to the synthetic nationally represen-
tative population (S2 Fig), rather than using the standard cut points established in the sub-na-
tional cohort studies (Table 1), would allow us to improve the specificity of some of the
instruments (S8 Table). Here, the recalibration involved choosing the cut point that maximized
the product of sensitivity and specificity (i.e., the point at the top- and left-most corner of the
ROC curves). This recalibration did not significantly change the NNS (Table 2, cf. S8 Table),
and the number of false positives would still remain between 40 million and 116 million, for a
false- to true-positive ratio of between 1.2 and 4.4.
Discussion
Our study finds that large-scale, population-wide screening for type 2 diabetes among adults in
India is unlikely to meet established criteria for implementing screening programs, which spec-
ify that such screening should utilize a reliably sensitive and specific instrument, and offer sig-
nificant therapeutic benefits to those individuals diagnosed through screening [11].
Our investigation adds several important findings to the existing literature. First, we found
that not all instruments tested previously in nonrepresentative subpopulations would be ex-
pected to work well in a nationally standardized large-scale screening program. For instance,
the popular Indian Diabetes Risk Score (the Mohan risk score) was found to have a sensitivity
no better than chance on average when extended to population-representative data, as opposed
to the data from the single city in which it was previously evaluated [8]. Recalibrating the in-
struments to a nationally representative population did not significantly impact the NNS to de-
tect one undiagnosed diabetes case. Second, among the instruments and approaches tested, we
found that very large numbers of false-positive screens would be expected. At a minimum, 126
million people who do not have diabetes would be labeled as high risk and referred for confir-
matory testing, and as many as 273 million false positives would be expected to be referred if
applying some currently proposed screening instruments. When including both false- and
true-positive screens, the burden on the health system would be expected to range from 158 to
306 million people referred to confirmatory testing, in order to detect an estimated 26 to 37
million people with currently undiagnosed diabetes. Third, among the screening options avail-
able, skipping the survey-based or random glucometer testing to proceed directly to fasting ve-
nous blood glucose appeared to significantly lower the NNS to find one previously
undiagnosed diabetes case, from between 15 and 22 persons down to 11 persons. It may be ar-
gued that adopting such a measure requires laboratory infrastructure, and thereby limits the
population reached through screening; conversely, the question remains how meaningful and
safe glucose-lowering therapy would be delivered to those individuals newly diagnosed in set-
tings without such capacity, given that screening processes must follow basic principles of non-
maleficence (i.e., “first do no harm”) [11].
The microsimulation results imply that the benefits of population-based diabetes screening
may be just as limited in India as in higher-income countries, where such screening has been
shown not to produce a significant reduction in all-cause, cardiovascular, or diabetes-related
mortality, or in rates of end-stage diabetes-related microvascular compilations such as
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blindness or renal failure. The studies in higher-income countries have involved cardiovascular
risk reduction measures among screen-detected diabetes patients, and target-based treatment
among diabetes patients detected through screening in high-risk populations [13,14]. In coun-
tries such as India where the burden of disease is rising in the context of healthcare system ca-
pacity limitations, a large-scale screening program bears the burden of demonstrating that the
system can handle the effort required to provide confirmatory testing and significantly benefi-
cial treatment among those screening positive and testing positive, respectively. Our assess-
ment calls into question the ability for this to be achieved in India, given the poor performance
of current screening instruments and the modest impact of early therapy for diabetes.
There are several strengths and some limitations of the present study. We conducted a com-
prehensive analysis that incorporates the most optimistic screening scenarios and iteratively
varies screening instruments across all plausible approaches. We additionally sampled among
diverse Indian populations to construct a nationally representative population for study. Yet,
as with all assessments of potential public health interventions, our model is based on impor-
tant assumptions. First, we used existing published cohort studies of diabetes prevalence.
While our assessment generated diabetes prevalence estimates matching independent esti-
mates, the cohort studies are still unlikely fully to capture the poorest and most rural areas of
the country, which are thought to have the lowest diabetes prevalence. This limitation would
tend to overstate the positive impacts of screening in our model. We additionally derived esti-
mates of treatment effects based on a model primarily developed among South Asians in the
UK, and using effect size estimates largely derived from clinical trials in higher-income popula-
tions. Further, to provide best-case estimates, we assumed that aggressive treatment goals (sys-
tolic blood pressure< 140 mm Hg, hemoglobin A1c< 7%, and LDL< 100 mg/dl) would be
reached, though these goals are rarely achieved even in developed countries and are clearly not
reflective of current treatment patterns in India [38]. We performed these calculations to pro-
vide relative magnitude estimates of treatment impact among newly screened versus previously
diagnosed patients, not to provide precise forecasts for cost-effectiveness analysis. Further-
more, we focused exclusively on type 2 diabetes, which is believed to comprise the vast majority
of diabetes cases in India; the screening approaches here are not valid for type 1 diabetes,
which would typically manifest among much younger age groups. Finally, we attached cost es-
timates based on currently available data on cost, but cost variations over space and time
would be expected to generate differences between expected and realized costs in practice.
Our findings have several implications for further research. In particular, we did not com-
pare alternative guidelines that are being advocated for treatment strategies among those newly
diagnosed with diabetes. The American Diabetes Association, World Health Organization, and
International Diabetes Federation guidelines all slightly differ in their suggested management
strategies for diabetes among adults, and would likely have different implications for patient
risk, safety, and system-level resource requirements [21,39,40]. A formal comparative effective-
ness assessment to tabulate the risks and benefits of each guideline-based treatment strategy is
needed. Furthermore, we found that a significant number of persons screening as high risk for
diabetes would also likely screen positive for untreated hypertension. While the mass screening
for asymptomatic diabetes may not produce significant treatment benefits given the limited
impact of early glycemic control for asymptomatic diabetes, further evaluation of mass screen-
ing approaches for hypertension, with secondary screening of hypertensive individuals for dia-
betes risk, may be a prudent approach. This is particularly important given that the major
cause of morbidity and mortality among people with type 2 diabetes in India and other low-
and middle-income countries is cardiovascular disease, and the major all-cause mortality risk
reduction benefit from diabetes treatment is from antihypertensive therapy rather than glyce-
mic control [41,42]. An alternative to disease-specific screening may be an approach that
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focuses not on detection of individual risk factors, but on global cardiovascular risk assessment,
based on a constellation of observed co-morbid risk factors ranging from diabetes to hyperten-
sion to tobacco smoking [43,44]. However, the benefit of cardiovascular risk assessment pro-
grams has been questioned, and their feasibility and cost-effectiveness in low- and middle-
income countries need to be carefully considered [45].
Despite the need for future research as suggested above, our current analysis suggests that
the existing and expanding large-scale diabetes screening program in India, which parallels the
programs being suggested for implementation in numerous low- and middle-income countries
[5,46], may have difficulties fulfilling basic criteria considered essential for effective large-scale
screening. The current analysis suggests that no population-based mass diabetes screening op-
tion can truly be recommended at present because of the vast expected number of false-positive
results. Hence, given our results, an approach that focuses on symptom-based screening, with
attendant treatment improvement among already-diagnosed persons, may be more sensible
than community-based mass screening. Improving instruments to reduce false-positive
screens, preparing the health system for very substantial confirmatory testing demands, and
identifying how to deliver efficacious treatment, are three priority areas that require urgent at-
tention before countries experiencing rapid increases in diabetes prevalence implement large-
scale community-based diabetes screening programs.
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Editors' Summary
Background
Worldwide, 387 million people have diabetes, a chronic condition characterized by high
levels of glucose (sugar) in the blood. Blood sugar levels are usually controlled by insulin, a
hormone released by the pancreas after meals. In people with type 2 diabetes (the most
common type of diabetes), blood sugar control fails because the fat and muscle cells that
normally respond to insulin by removing excess sugar from the blood become less respon-
sive to insulin. Risk factors for diabetes include being overweight, having a large waist,
being physically inactive, and having a family history of diabetes. The symptoms of diabe-
tes, which develop slowly, include excessive urination at night and unexplained weight
loss. Type 2 diabetes can usually be controlled initially with diet and exercise and with an-
tidiabetic drugs such as metformin and sulfonylureas, but many patients eventually need
insulin injections. Long-term complications of diabetes, which include an increased risk of
heart disease and stroke, reduce the life expectancy of people with diabetes by about 10
years compared to people without diabetes.
WhyWas This Study Done?
Diabetes is becoming increasing common, particularly in rapidly developing countries,
but most people with diabetes in these countries are unaware that they have the condition.
Because the risk of developing diabetic complications is reduced by careful blood sugar
control, it is important to identify and treat anyone who has diabetes as early as possible.
Some rapidly developing countries are therefore beginning to develop systems for large-
scale community-based screening for diabetes (even though the UK has recently decided
against such screening). In India, for example, more than 53 million adults living in rural
and urban communities have already been screened using either questionnaires designed
to provide a risk score (survey-based screening) or random blood glucose testing (gluc-
ometer-based screening). People who are identified as “high risk” using these approaches
are referred for fasting blood glucose tests to confirm the diagnosis. Although the Indian
government plans to expand this screening program, no data have been collected to track
its performance. Here, the researchers develop a microsimulation model (a computer
model that operates at the level of individuals) to investigate the implications of using al-
ternative screening instruments to identify people with undetected diabetes across diverse
populations in India.
What Did the Researchers Do and Find?
The researchers constructed a synthetic nationally representative population of Indians
aged 25–65 years using data from 58 sub-national studies. They then used their microsi-
mulation model to estimate the diagnostic and health system implications of using three
survey-based screening instruments and glucometer-based screening to identify individu-
als in this population with diabetes. Depending on which approach was used for screening,
between 158 million and 306 million of the 567 million Indians eligible for screening
would be classified as high risk for diabetes and would be referred for confirmatory testing,
according to the model. However, between 126 million and 273 million of these high-risk
individuals would be false positives; only between 26 million and 37 million of these indi-
viduals would meet the international diagnostic criteria for diabetes (true positives). The
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researchers estimate that the cost per case found would vary from US$5.28 (when using
random glucose screening) to US$17.06 (when using a survey-based screening instru-
ment). Finally, they estimate that the total cost for screening the eligible population would
be between US$169 and US$567 million.
What Do These Findings Mean?
Established criteria for implementing screening programs specify that such programs
should use reliable instruments that detect a large proportion of true cases (high sensitivi-
ty) and that have a low rate of false positives (high specificity). Screening programs should
also offer significant therapeutic benefits to individuals diagnosed through screening. The
findings of this study suggest that large-scale community-based screening for diabetes in
India using the currently available screening instruments is unlikely to meet these criteria.
Indeed, because the data used to construct the synthetic population came from published
studies that did not capture the situation in the poorest, most rural areas of India, where
the proportion of the population with diabetes is thought to be lowest, these findings may
overestimate the efficacy and health benefits of screening. The researchers suggest, there-
fore, that an approach that focuses on symptom-based screening and on improvements in
the treatment of already diagnosed individuals might be a more sensible path for India to
take to deal with its burgeoning diabetes epidemic than community-based mass screening.
Additional Information.
Please access these websites via the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001827.
• The US National Diabetes Information Clearinghouse provides information about dia-
betes for patients, healthcare professionals, and the general public (in English and
Spanish)
• The UK National Health Service Choices website provides information for patients and
caregivers about type 2 diabetes and about living with diabetes; it also provides people’s
stories about diabetes
• The charity Diabetes UK provides detailed information for patients and caregivers in
several languages
• The UK-based non-profit organization HealthTalkOnline has interviews with people
about their experiences of diabetes
• MedlinePlus provides links to further resources and advice about diabetes (in English
and Spanish)
• A statement from the UK National Screening Committee on diabetes screening in adults
is available
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